Table 2 Demographics, clinical practice parameters and prognosis of study groups
Year | 2014 | 2015 | 2016 | |||
|---|---|---|---|---|---|---|
Study group (number) | AS-2014 (n = 141,782) | NAS-2014 (n = 427,471) | AS-2015 (n = 142,790) | NAS-2015 (n = 414,892) | AS-2016 (n = 143,339) | NAS-2016 (n = 396,369) |
Demographics | ||||||
 Age, mean ± SD | 69.9 ± 10.1 | 65.8 ± 13.9 | 70.0 ± 10.1 | 66.7 ± 14.0 | 70.1 ± 10.1 | 67.5 ± 14.1 |
 Sex, male (%) | 101,795 (71.8) | 247,710 (57.9) | 103,882 (72.8) | 237,278 (57.2) | 106,664 (74.4) | 221,506 (55.9) |
Clinical practice parameters | ||||||
 PFT conduction (%) | 85,392 (60.2) | 106,073 (24.8) | 91,084 (63.8) | 115,435 (27.8) | 98,895 (69.0) | 110,957 (27.8) |
 Inhaled LAMA prescription (%) | 63,932 (45.1) | 14,112 (3.3) | 69,833 (48.9) | 21,038 (5.1) | 74,254 (51.8) | 20,247 (5.1) |
 Inhaled LABA prescription (%) | 70,091 (49.4) | 74,039 (17.3) | 76,597 (53.6) | 77,233 (18.6) | 76,508 (53.4) | 71,593 (18.1) |
 ICS prescription (%) | 82,331 (58.1) | 223,413 (52.3) | 81,284 (56.9) | 213,943 (51.6) | 81,242 (56.7) | 202,562 (51.1) |
 SABA prescription (%) | 51,066 (36.0) | 38,965 (9.1) | 30,158 (21.1) | 39,191 (9.5) | 29,931 (20.9) | 37,786 (9.5) |
Prognosis | ||||||
 Frequency of admission for COPD/yr, mean ± SD | 0.307 ± 1.062 | 0.091 ± 0.634 | 0.281 ± 1.002 | 0.100 ± 0.695 | 0.296 ± 1.065 | 0.111 ± 0.777 |
 All-cause mortality in the next year (%) | 8278 (5.8) | 9672 (2.3) | 8217 (5.8) | 12,897 (3.1) | 8341 (5.8) | 15,076 (3.8) |